Gland Pharma Ltd.
GLAND · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,648.25.
Piotroski F-score 8/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%10.5%
- ✓Low debt (D/E < 0.5)0.03x
- ✓Positive free cash flow
- ✓Revenue growth > 10%22%
- ✓Earnings growing96%
- ✓Net margin ≥ 10%16.0%
- ✓Current ratio > 1.54.68
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 12.06
- ✓Piotroski ≥ 78/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (16.0%).
- •Financially solid — Altman Z 12.06.
- •High Piotroski quality score (8/9).
Opportunities
- •Earnings growing (96% YoY).
- •Revenue growing (22% YoY).
- •Trading in our value buy zone versus sector peers.
About Gland Pharma Ltd.
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categorie
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.